Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

GLP-1 agonist medications such as Ozempic accounted for 10% of the North Carolina state employee health plan’s prescription ...

A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% of their body weight. But the drugs don’t work ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

The outgoing Biden administration is proposing to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare ...

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.